Search Results - "Lecot, Jean"

Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen in mild asthma by Gauvreau, Gail M, Hohlfeld, Jens M, FitzGerald, J Mark, Boulet, Louis-Philippe, Cockcroft, Donald W, Davis, Beth E, Korn, Stephanie, Kornmann, Oliver, Leigh, Richard, Mayers, Irvin, Watz, Henrik, Grant, Sarah S, Jain, Monish, Cabanski, Maciej, Pertel, Peter E, Jones, Ieuan, Lecot, Jean R, Cao, Hui, O'Byrne, Paul M

“…Thymic stromal lymphopoietin (TSLP) is a key upstream regulator driving allergic inflammatory responses. We evaluated the efficacy and safety of ecleralimab, a…”
Get full text

Effects of triclabendazole and its metabolite exposure on the heart‐rate–corrected QT intervals: A randomized, placebo‐ and positive‐controlled thorough QT study in healthy individuals by Prince, William T., Venishetty, Vinay Kumar, Lecot, Jean, Shakeri‐Nejad, Kasra, Gray, Cathy, Taylor, Amanda, Iyer, Ganesh R., Zack, Julia

“…Abstract Triclabendazole is an effective and well‐tolerated treatment for human fascioliasis. A placebo‐ and positive‐controlled, four‐sequence by four‐period…”
Get full text

A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features by Ruperto, Nicolino, Quartier, Pierre, Wulffraat, Nico, Woo, Patricia, Ravelli, Angelo, Mouy, Richard, Bader-Meunier, Brigitte, Vastert, Sebastiaan J., Noseda, Emanuele, D'Ambrosio, Daniele, Lecot, Jean, Chakraborty, Abhijit, Martini, Alberto, Chioato, Andrea

“…Objective To assess dosing, preliminary safety, and efficacy of canakinumab, a fully human anti–interleukin‐1β (anti–IL‐1β) antibody, in children with systemic…”
Get full text

Concentration‐QTcF Modeling of Icenticaftor from a Randomized, Placebo‐ and Positive‐Controlled Thorough QT Study in Healthy Participants by Iyer, Ganesh R., Darpo, Borje, Xue, Hongqi, Lecot, Jean, Zack, Julia, Bebrevska, Lidiya, Weis, Wendy, Jones, Ieuan, Drollmann, Anton

“…Icenticaftor (QBW251) is a potentiator of the cystic fibrosis transmembrane receptor. Based on its mechanism of action, icenticaftor is expected to provide…”
Get full text